pSivida Corp. Reports Second Quarter FY2018 Results

pSivida (NASDAQ:PSDV) a leader in the development of sustained release drug products and technologies, today reported financial results for its fiscal 2018 second quarter and six months ended December 31, 2017 and provided an update on its continued operating progress.

As quoted in the press release:

“We achieved several milestones in the fiscal second quarter and the past few weeks and continue to make material progress in the transformation of pSivida into a fully integrated commercial stage pharmaceutical enterprise,” commented Nancy Lurker, President & CEO.

Click here to read the full press release.